COVID 19 Clinical Trial
Official title:
AiM COVID for Covid 19 Tracking and Prediction
| NCT number | NCT04354753 |
| Other study ID # | AU12 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | March 28, 2020 |
| Est. completion date | April 17, 2020 |
| Verified date | April 2020 |
| Source | Aarogyam UK |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
University of Warwick (Coventry, UK) and NTUU "Igor Sikorsky" Kyiv Polytechnic Institute (Kyiv, Ukraine), together with ClickMedix LLC, have developed an app and a chatbot "AiM COVID" for efficient monitoring and mitigation of COVID-19. These products are available for free download on computers and mobile phones. These can be used by a wide range of users from various sectors - patients and people living with them, doctors, nurses, specialists, community health workers, hospitals, clinics, hospital IT staff, MHFA, and insurance companies.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | April 17, 2020 |
| Est. primary completion date | April 14, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Participants 18 and above - living in UK - reported with or without symptoms from February 28 to March 28 with community support groups Exclusion Criteria: - below 18 years old |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Aarogyam (UK) | Leicester |
| Lead Sponsor | Collaborator |
|---|---|
| Aarogyam UK | ClickMedix LLC, Igor Sikorsky Kyiv Polytechnic Institute, University of Warwick |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Physical symptoms | Self reported physical symptoms | 1day | |
| Primary | Contact History | Contact with suspected, confirmed or ill person | 14 days | |
| Primary | Travel History | Travel to or from overseas | 14 days | |
| Secondary | Fever | Self reported body temperature | 1 day | |
| Secondary | Headache | Self reported headache using yes/no | 1 day | |
| Secondary | Soar Throat | Self reported soar throat using yes/no | 1 day | |
| Secondary | Runny nose | Self reported runny nose using yes/no | 1 day | |
| Secondary | Cough | Self reported cough using yes/no | 1 day | |
| Secondary | Shortness of breath | Self reported shortness of breath symptoms using yes/no | 1 day | |
| Secondary | Nausea | Self reported nausea using yes/no | 1 day | |
| Secondary | Vomiting | Self reported vomiting using yes/no | 1 day | |
| Secondary | Muscle pain | Self reported muscle pain using yes/no | 1 day | |
| Secondary | Joint pain | Self reported joint pain using yes/no | 1 day | |
| Secondary | Diarrhoea | Self reported Diarrhoea using yes/no | 1 day | |
| Secondary | Other | Self reported other symptoms using yes/no | 1 day | |
| Secondary | Hospitalisation history | Self reported hospitalisation using yes/no | 1 day | |
| Secondary | Co-morbid conditions | Self reported co-morbid conditions using checked box | 1 day |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
| Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
| Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
| Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
| Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
| Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
| Active, not recruiting |
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 | |
| Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
| Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
| Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
| Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
| Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
| Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
| Completed |
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 |